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Introduction
No evidence-based classification criteria are so far avail-
able for the majority of autoinflammatory diseases
Objectives
To elaborate and validate a set of clinical criteria able to
correctly classify patients affected with the most com-
mon periodic fevers
Methods
All FMF, TRAPS, MKD and CAPS patients enrolled in
the Eurofever registry until March 2013 were evaluated.
For each disease gold standards were considered accord-
ing to the following criteria: i) clinical validation by cen-
ters and disease-principal investigator, ii) confirmative
molecular analysis (2 mutations for MEFV with at least
one mutation in exon 10, 2 mutations of MVK gene,
1 mutation of TNFRFS1A with exclusion of low-pene-
trance variants, 1 mutation of NLRP3 with exclusion of
low-penetrance variants), iii) PFAPA patients validated
by disease-principal investigator and confirmed by the
centers on the basis of the follow-up. Clinical criteria
were formulated on the basis of a univariate and multi-
variate analysis in a first group of patients (training set)
and then validated in an independent set of patients
(validation set).
Results
A total of 1204 consecutive patients with periodic fevers
were enrolled in the registry. Among them 743 consecu-
tive gold standard patients (288 FMF, 73 MKD, 96
TRAPS, 87 CAPS, 199 PFAPA) were evaluated (440 in
the training set and 303 in the validation set). The mul-
tivariate analysis identified the clinical variables (either
as presence or absence) independently correlated to for
each disease with their specific weight. The cut off value
of the classification score was chosen on the ROC curve
in order to guarantee the highest sensitivity and
specificity.
The classification score was than tested in an indepen-
dent set of patients (validation set) revealing a sensitivity
of 93% and specificity of 89% for FMF; a sensitivity of
100% and specificity of 74% for TRAPS; a sensitivity of
80% and specificity of 90% for MKD and sensitivity
of 97% and specificity of 92% for CAPS; sensitivity of
99% and specificity of 96% for PFAPA. The performance
in non-gold standard patients (i.e. heterozygous patients
in autosomal recessive diseases or patients with low-
penetrance mutations) revealed a variable percentage of
patients (70% FMF, 75% TRAPS, 41% MKD and 94%
CAPS) positive for the respective criteria.
Conclusion
Evidence-based clinical criteria for the classification of
patients with inherited periodic fevers have been elabo-
rated. These clinical criteria could be used in association
with molecular analysis and other variables (i.e. meta-





12nd Division of Pediatric, Gaslini Institute, Genoa, Italy. 2Department of
Pediatric Nephrology&Rheumatology, Hacettepe University, Faculty of
Medicine, Ankara, Turkey. 3Division of Pediatric Rheumatology, Bicêtre
12nd Division of Pediatric, Gaslini Institute, Genoa, Italy
Full list of author information is available at the end of the article
Federici et al. Pediatric Rheumatology 2013, 11(Suppl 2):O29
http://www.ped-rheum.com/content/11/S2/O29
© 2013 Federici et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hospital, Paris, France. 4University College Medical School, London, UK. 5UCL,
London, UK. 6Rheumatology Unit, University of Siena, Siena, Italy.
7Republican Children’s FMF Center, Yerevan State Medical University,
Yerevan, Armenia. 8Department of rheumatology, Ospedale Bambin Gesù,
Rome, Italy. 9Division of Pediatric Rheumatology, University Hospital
Tübingen, Tuebingen, Germany. 10Hôpital Necker-Enfants Malades, Paris,
France. 11Gaslini Institute, Genoa, Italy. 12Department of Paediatrics, Meir
Medical Center, Kfar Saba, Israel. 13Department of Pediatric Sciences,
Università Cattolica del Sacro Cuore, Roma, Italy. 14Department of Pediatrics,
Aarhus University Hospital, Aarhus, Denmark. 15Clinica Pediatrica, University
of Torino, Torino, Italy. 16Department of General Internal Medicine, Radboud
University of Nijmegen Medical Center, Nijmegen, The Netherlands.
17National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH,
Bethesda, USA. 18Department of Internal Medicine, Istanbul University,
Istanbul, Turkey. 19University Medical Center Utrecht, Utrecht, The
Netherlands. 20Centre Multisite Romand de Rhumatologie Pediatrique, CHUV,
Lausanne, Switzerland.
Published: 5 December 2013
doi:10.1186/1546-0096-11-S2-O29
Cite this article as: Federici et al.: PReS-FINAL-2194: Evidence-based
clinical classification criteria for periodic fevers. Pediatric Rheumatology
2013 11(Suppl 2):O29.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Federici et al. Pediatric Rheumatology 2013, 11(Suppl 2):O29
http://www.ped-rheum.com/content/11/S2/O29
Page 2 of 2
